



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

9th November, 2022

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir / Madam,

Please find enclosed herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 12 /2022-23

9th November, 2022

**NATCO Announces Launch of First Generic Version of Pomalyst®
(Pomalidomide) Capsules in the Australian Market**

Hyderabad, India, 9th November 2022

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the launch of first **generic version of Pomalyst® (Pomalidomide) Capsules** in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO's commercial partner **Juno Pharmaceuticals Pty Ltd.**

Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. For more information refer to the full prescribing information or other medical resources.

Pomalyst® registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.

Pomalyst® is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer